Repligen Q4 revenue flat YoY at $186.8M; guides 2023 revenue down 5% to $760-800M

REPLIGEN CORP

2022-FY EPS reported $3.24 revenue$801,536,000

Q4 GAAP EPS $0.85 (up from $0.50 YoY); adjusted EPS $0.68 (down from $0.81).
Full year 2022 revenue $801.5M (+20% YoY); base organic growth 39%.
2023 guidance: revenue $760-800M (down from 2022 due to $100-110M COVID decline); base organic growth 12-16%.
Gross margin declines: Q4 GAAP 51.4% (down 460 bps), full year 56.9%; 2023 guided 52.5-53.5%.
Launched 10 new products in 2022; cell/gene therapy revenue grew >50%; signed 2 partnerships.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REPLIGEN CORP reported financial results for the fourth quarter and year end December 31, 2022.

Period: the fourth quarter and year end December 31, 2022
Result: reported results

Exact text from the filing

On February 22, 2023, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2022.

View on SEC.gov

Browse all earnings releases →

REPLIGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-23-044164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.